Integra LifeSciences (NASDAQ:IART) Sets New 1-Year High – What’s Next?

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $17.83 and last traded at $17.3850, with a volume of 133133 shares. The stock had previously closed at $17.56.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IART. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Wells Fargo & Company raised their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Truist Financial dropped their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $14.00.

Integra LifeSciences Stock Performance

The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The stock has a fifty day moving average of $12.32 and a 200-day moving average of $11.95. The stock has a market cap of $1.33 billion, a PE ratio of -2.64, a price-to-earnings-growth ratio of 1.12 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same quarter last year, the company posted $0.41 earnings per share. The business’s revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC purchased a new position in shares of Integra LifeSciences during the fourth quarter worth about $25,000. Osaic Holdings Inc. grew its holdings in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after buying an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Integra LifeSciences in the 4th quarter valued at approximately $124,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.